Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Formycon AG (GB:0W4N)
LSE:0W4N
Formycon AG (0W4N) Share Price & Analysis
0 Followers
0W4N Stock Chart & Stats
Day’s Range€39.1 - €39.95
52-Week Range― - ―
Previous Close€40
Volume213.00
Average Volume (3M)N/A
Market Cap
€690.38M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 15, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€93.67Price Target Upside139.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Drug ApprovalHealth Canada's approval of Ranopto/FYB201 for serious retinal diseases represents a significant step forward for Formycon, potentially boosting its market presence and sales in Canada.
Financial ForecastAnalyst expectations point to Formycon's FYB201 reaching substantial peak sales, which could strongly enhance the company's revenue profile.
Regulatory MilestoneThe submission of Formycon's marketing authorisation application for FYB203, a biosimilar of Eylea, to the European Medicines Agency marks a pivotal moment, potentially unlocking a lucrative market in Europe.
Bears Say
Competitive ThreatA direct competitor in the Stelara biosimilar market has negotiated a settlement that permits an earlier market entry of their biosimilar product, preceding Formycon's planned commercialization.
Sales PerformanceCimerli's sales performance in the US market has not met analyst estimates, raising concerns about the product's revenue generation capabilities.
Stock PerformanceThe stock has underperformed in comparison to the Scale All Share Index, with a relative performance downturn that could signal investor skepticism in the company's market position.
---
Options Prices
Currently, No data available
---
Ownership Overview
13.93% Insiders
0.05% Mutual Funds
0.38% Other Institutional Investors
85.64% Public Companies and
Individual Investors
0W4N FAQ
What was Formycon AG’s price range in the past 12 months?
Currently, no data Available
What is Formycon AG’s market cap?
Currently, no data Available
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s upcoming earnings report date is May 15, 2024 which is in 20 days.
How were Formycon AG’s earnings last quarter?
Currently, no data Available
Is Formycon AG overvalued?
According to Wall Street analysts Formycon AG’s price is currently Undervalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Formycon AG have?
Currently, no data Available
What happened to Formycon AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in GB:0W4N
---
Formycon AG Stock Smart Score
Company Description
Formycon AG
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
---
0W4N Stock 12 Months Forecast
Average Price Target
€93.67
▲(139.57% Upside)
Technical Analysis
Best Analysts Covering 0W4N
1 Year
1 Year Success Rate
0/9 ratings generated profit
1 Year Average Return
-28.67%
reiterated a buy rating 4 days ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -28.67% per trade.
---